Literature DB >> 323525

Propranolol in the treatment of essential hypertension.

.   

Abstract

In a series of 450 patients with mild essential hypertension, propranolol alone (P), propranolol plus hydrochlorothiazide (P+T), propranolol plus hydralazine (P+H), and propranolol plus hydrochlorothiazide plus hydralazine (P+T+H) were compared to reserpine plus hydrochlorothiazide (R+T). Comparison was based on reduction of diastolic blood pressures (BP) to below 90 mm Hg and at least 5 mm Hg less than initial BP after six months of treatment. This was achieved in 92% of patients who received P+T+H, 88% taking R+T, 81% receiving P+T, 72% on P+H and 52% taking P alone. The number of drop-outs, morbid events, and terminating side effects were insignificantly different among the various regimens. In this study, P and P+H were less effective, while P+T and P+T+H were as effective as the standard regimen.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 323525

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  15 in total

Review 1.  [Reserpine-diuretic combinations in therapy of arterial hypertension. Current considerations].

Authors:  M Siepmann; W Kirch
Journal:  Med Klin (Munich)       Date:  1998-12-15

Review 2.  Reserpine: a relic from the past or a neglected drug of the present for achieving cost containment in treating hypertension?

Authors:  G J Magarian
Journal:  J Gen Intern Med       Date:  1991 Nov-Dec       Impact factor: 5.128

Review 3.  Fixed-dose combination antihypertensive drugs. Do they have a role in rational therapy?

Authors:  D A Sica
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

4.  Ketanserin, an effective third-line agent in primary hypertension.

Authors:  J J Murphy; P H Whincup; S E Gould; R G Wilcox
Journal:  Drugs       Date:  1988       Impact factor: 9.546

5.  How useful is riboflavin as a tracer of medication compliance?

Authors:  I E Babiker; P R Cooke; M G Gillett
Journal:  J Behav Med       Date:  1989-02

6.  Central effects of combined bendrofluazide and atenolol administration. A single dose study in normal subjects.

Authors:  L Gerrard; N M Wheeldon; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: a new vasodilator.

Authors:  E G Breen; D Mulhall; J A Keogh
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 8.  Drug treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1988       Impact factor: 9.546

9.  Riboflavin as a tracer of medication compliance.

Authors:  P M Dubbert; A King; S R Rapp; D Brief; J E Martin; M Lake
Journal:  J Behav Med       Date:  1985-09

10.  Assessment of riboflavin as a tracer substance: comparison of a qualitative to a quantitative method of riboflavin measurement.

Authors:  Abigail J Herron; John J Mariani; Martina Pavlicova; Christina M Parrinello; Krysten W Bold; Frances R Levin; Edward V Nunes; Maria A Sullivan; Wilfred N Raby; Adam Bisaga
Journal:  Drug Alcohol Depend       Date:  2012-08-22       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.